Наукова електронна бібліотека
періодичних видань НАН України

Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?

Репозиторій DSpace/Manakin

Показати простий запис статті

dc.contributor.author Naumnik, W.
dc.contributor.author Naumnik, B.
dc.contributor.author Niewiarowska, K.
dc.contributor.author Ossolinska, M.
dc.contributor.author Chyczewska, E.
dc.date.accessioned 2018-06-21T12:58:45Z
dc.date.available 2018-06-21T12:58:45Z
dc.date.issued 2012
dc.identifier.citation Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? / W. Naumnik, B. Naumnik, K. Niewiarowska, M. Ossolinska, E. Chyczewska // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 348-353. — Бібліогр.: 31 назв. — англ. uk_UA
dc.identifier.issn 1812-9269
dc.identifier.uri http://dspace.nbuv.gov.ua/handle/123456789/139877
dc.description.abstract There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before chemotherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are significantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A negative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies. uk_UA
dc.description.sponsorship We are indebted to Robert Mroz for his help with the ELISA equipment. This work was granted by Polish Ministry of Science and Higher Education (NN 401 230134; 2301/B/P01/2008/34). uk_UA
dc.language.iso en uk_UA
dc.publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України uk_UA
dc.relation.ispartof Experimental Oncology
dc.subject Original contributions uk_UA
dc.title Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? uk_UA
dc.type Article uk_UA
dc.status published earlier uk_UA


Файли у цій статті

Ця стаття з'являється у наступних колекціях

Показати простий запис статті

Пошук


Розширений пошук

Перегляд

Мій обліковий запис